Growth Metrics

Pfizer (PFE) Long-Term Deferred Tax (2016 - 2025)

Pfizer (PFE) has disclosed Long-Term Deferred Tax for 17 consecutive years, with $9.7 billion as the latest value for Q4 2025.

  • On a quarterly basis, Long-Term Deferred Tax rose 11.97% to $9.7 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $9.7 billion, a 11.97% increase, with the full-year FY2025 number at $9.7 billion, up 11.97% from a year prior.
  • Long-Term Deferred Tax was $9.7 billion for Q4 2025 at Pfizer, down from $11.0 billion in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $11.0 billion in Q3 2025 to a low of $2.5 billion in Q2 2021.
  • A 5-year average of $6.8 billion and a median of $7.2 billion in 2022 define the central range for Long-Term Deferred Tax.
  • Peak YoY movement for Long-Term Deferred Tax: skyrocketed 159.91% in 2022, then tumbled 44.63% in 2023.
  • Pfizer's Long-Term Deferred Tax stood at $3.3 billion in 2021, then skyrocketed by 100.33% to $6.7 billion in 2022, then crashed by 44.63% to $3.7 billion in 2023, then soared by 133.73% to $8.7 billion in 2024, then grew by 11.97% to $9.7 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Long-Term Deferred Tax are $9.7 billion (Q4 2025), $11.0 billion (Q3 2025), and $10.3 billion (Q2 2025).